The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Phase II clinical trial (the "Study") of UBT251 Injection, a Class 1 innovative drug independently developed by The United Bio-Technology (Hengqing) Co., Ltd. ("United Biotechnology"), a wholly-owned subsidiary of the Company, has been completed in Chinese patients with overweight/obesity.

The Study adopted a randomized, double-blind, parallel, placebo-controlled trial design, and enrolled a total of 205 patients with obesity (BMI $\geq$ 28.0 kg/m²) or overweight (24.0 kg/m² $\leq$ BMI < 28.0 kg/m²) accompanied by at least one weight-related comorbidity. The baseline mean body weight of the patients was 92.2 kg, with a baseline mean BMI of 33.1 kg/m². Patients were randomly assigned in a 1:1:1:1 ratio to the UBT251 Injection 2 mg, 4 mg, 6 mg or placebo group. Each dose group was administered subcutaneously injection once a week for 24 consecutive weeks, and the primary endpoint of the Study was the percentage change (%) in body weight from baseline after 24 weeks of treatment.

The Study results showed that all dose groups of UBT251 demonstrated significant weight-loss effects. At Week 24, the maximum mean body weight change from baseline was -19.7% (-17.5 kg) in the UBT251 groups, while -2.0% (-1.6 kg) in the placebo group. Moreover, all dose groups of UBT251 showed significantly greater improvements in key secondary endpoints, including waist circumference, blood glucose, blood pressure and blood lipids, relative to placebo group. Overall, all dose groups of UBT251 showed good safety and tolerability, with no patients withdrawn due to any adverse events. Adverse events were similar to those of drugs in the same class, mainly gastrointestinal reactions, the vast majority of which were mild to moderate, and no unexpected safety signals were observed.

The Phase II clinical trial of UBT251 Injection in overweight/obese patients achieved the expected results, supporting its progression to the next stage of clinical study. The Company will subsequently initiate a Phase III clinical trial in Chinese patients with overweight/obesity in a timely manner.

ABOUT UBT251

UBT251 is a long-acting triple-target receptor agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon). To date, the Company has been approved to conduct clinical trials in China and/or the United States for multiple indications including adult type 2 diabetes, overweight/obesity, chronic kidney disease ("CKD") and metabolic dysfunction-associated steatohepatitis ("MASH"). The Company is the first enterprise in China and the second in the world to be approved for clinical trials of a long-acting triple agonist of GLP-1R/GIPR/GCGR prepared by chemical synthesis polypeptide method.

In March 2025, United Biotechnology and the Company entered into an exclusive license agreement with Novo Nordisk A/S for UBT251.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 24 February 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.